Baker McKenzie advised Modag GmbH on the deal. Blomstein advised Teva Pharmaceutical Industries Limited.
MODAG GmbH signed a collaboration agreement with Teva Pharmaceutical Industries Ltd. on the exclusive worldwide licensing and development of MODAG’s lead compound anle138b and the related compound, sery433 and joined development of the lead compound for the multiple system atrophy.
MODAG, a privately held German biotech company, is focused on the research and development of therapeutics and diagnostics for neurodegenerative diseases.
The Baker McKenzie team was led by Corporate/M&A partner Berthold A. Hummel (Picture); Transactional IP: Julia Schieber (senior associate, Zurich); and also included Corporate/M&A: Julia Braun (partner, Munich), Michelle Karrer (associate, Munich); IP: Jane Hobson (partner, London), Oren Livne (partner, New York), Pete Chapman (senior associate, London), Indhu Birdy (senior associate, London); Antitrust & Trade: Dr. Christian Burholt (partner, Berlin), Katrin Kurz (associate, Berlin), Ann-Kristin Freiheit (associate, Frankfurt); Foreign Trade Law: Anahita Thoms (partner, Berlin), Alexander Ehrle (associate, Berlin).
The Blomstein team consisted of Roland M. Stein, Leonard von Rummel, Bruno Galvão and Vanessa Kassem.
Involved fees earner: Indhu Birdy – Baker McKenzie; Julia Braun – Baker McKenzie; Christian Burholt – Baker McKenzie; Pete Chapman – Baker McKenzie; Alexander Ehrle – Baker McKenzie; Ann-Kristin Freiheit – Baker McKenzie; Jane Hobson – Baker McKenzie; Berthold Hummel – Baker McKenzie; Michelle Karrer – Baker McKenzie; Katrin Kurz – Baker McKenzie; Oren Livne – Baker McKenzie; Julia Schieber – Baker McKenzie; Anahita Thoms – Baker McKenzie; Vanessa Kassem – Blomstein; Roland Stein – Blomstein; Leonard Freiherr von Rummel – Blomstein;